Sign up
Pharma Capital

Avacta building on 'significant' commercial momentum for Affimer technology

Dr Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive they've been making significant technical and commercial headway with their Affimer technology, as part of the firm's trading update for the year to the end of July 2017.

''It's been 12 months of significant de-risking of the therapeutic platform ... it's been a significant period of progress for us'', Dr Smith says.

 

View full AVCT profile View Profile
CN Video

Riccardo Lowi discusses Avacta

CN Research

Avacta Group Plc - On track and undervalued

View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.